Jiajia Xu , Jiaqi Zhu , Weiyao Han , Siqi Pang , Simin Deng , Long Chen , Xiabing Chen , Qi Huang , Rui Zhou , Lu Li
{"title":"A bifunctional amylopullulanase of Streptococcus suis ApuA contributes to immune evasion by interaction with host complement C3b","authors":"Jiajia Xu , Jiaqi Zhu , Weiyao Han , Siqi Pang , Simin Deng , Long Chen , Xiabing Chen , Qi Huang , Rui Zhou , Lu Li","doi":"10.1016/j.vetmic.2024.110212","DOIUrl":null,"url":null,"abstract":"<div><p>The complement system is the first defense line of the immune system. However, pathogens have evolved numerous strategies to evade complement attacks. <em>Streptococcus suis</em> is an important zoonotic bacterium, harmful to both the pig industry and human health. ApuA has been reported as a bifunctional amylopullulanase and also contributed to virulence of <em>S. suis</em>. Herein, we found that ApuA could activate both classical and alternative pathways of the complement system. Furthermore, by using bacterial two-hybrid, far-western blot and ELISA assays, it was confirmed that ApuA could interact with complement C3b. The interaction domain of ApuA with C3b was found to be its α-Amylase domain (ApuA_N). After construction of an <em>apuA</em> mutant (Δ<em>apuA</em>) and its complementary strain, it was found that compared to the wild-type strain (WT), Δ<em>apuA</em> had significantly increased C3b deposition and membrane attack complex formation. Additionally, Δ<em>apuA</em> showed significantly lower survival rates in human serum and blood and was more susceptible to engulfment by neutrophils and macrophages. Mice infected with Δ<em>apuA</em> had significantly higher survival rates and lower bacterial loads in their blood, lung and brains, compared to those infected with WT. In summary, this study identified ApuA as a novel factor involved in the complement evasion of <em>S. suis</em> and suggested its multifunctional role in the pathogenesis of <em>S. suis</em>.</p></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"297 ","pages":"Article 110212"},"PeriodicalIF":2.4000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113524002347","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The complement system is the first defense line of the immune system. However, pathogens have evolved numerous strategies to evade complement attacks. Streptococcus suis is an important zoonotic bacterium, harmful to both the pig industry and human health. ApuA has been reported as a bifunctional amylopullulanase and also contributed to virulence of S. suis. Herein, we found that ApuA could activate both classical and alternative pathways of the complement system. Furthermore, by using bacterial two-hybrid, far-western blot and ELISA assays, it was confirmed that ApuA could interact with complement C3b. The interaction domain of ApuA with C3b was found to be its α-Amylase domain (ApuA_N). After construction of an apuA mutant (ΔapuA) and its complementary strain, it was found that compared to the wild-type strain (WT), ΔapuA had significantly increased C3b deposition and membrane attack complex formation. Additionally, ΔapuA showed significantly lower survival rates in human serum and blood and was more susceptible to engulfment by neutrophils and macrophages. Mice infected with ΔapuA had significantly higher survival rates and lower bacterial loads in their blood, lung and brains, compared to those infected with WT. In summary, this study identified ApuA as a novel factor involved in the complement evasion of S. suis and suggested its multifunctional role in the pathogenesis of S. suis.
补体系统是免疫系统的第一道防线。然而,病原体已经进化出许多策略来躲避补体的攻击。猪链球菌是一种重要的人畜共患细菌,对养猪业和人类健康都有害。据报道,ApuA 是一种双功能淀粉兜兰酶,也是猪链球菌毒力的来源之一。在此,我们发现 ApuA 可激活补体系统的经典和替代途径。此外,通过使用细菌双杂交、远西印迹和酶联免疫吸附试验,证实了 ApuA 能与补体 C3b 相互作用。研究发现 ApuA 与 C3b 的相互作用结构域是其α-淀粉酶结构域(ApuA_N)。在构建了 apuA 突变体(ΔapuA)及其互补菌株后,发现与野生型菌株(WT)相比,ΔapuA 的 C3b 沉积和膜攻击复合物形成显著增加。此外,ΔapuA 在人血清和血液中的存活率明显降低,而且更容易被中性粒细胞和巨噬细胞吞噬。与感染 WT 的小鼠相比,感染 ΔapuA 的小鼠存活率明显更高,血液、肺部和大脑中的细菌量也更低。总之,本研究发现 ApuA 是一种参与猪链球菌补体回避的新型因子,并提示了它在猪链球菌发病机制中的多功能作用。
期刊介绍:
Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal.
Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge.
Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.